XNAS
FDMT
Market cap678mUSD
Oct 20, Last price
13.10USD
1D
1.24%
1Q
8.04%
IPO
-69.65%
Name
4D Molecular Therapeutics Inc
Chart & performance
P/E
—
P/S
8.49
EPS
—
Vol. 1Y
77.34%
Shs. 5Y
16.77%
Rev. 5Y
44.32%
Div Yld LY
—
Div Yld TTM
—
Revenues
85m
+230,194.59%
Net income
-140m
L-12.90%
CFO
-109m
L-18.95%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Key people
Executive Chairman of the Board · since 2020
Fariborz Kamal
President, Chief Operating Officer · since 2022
David Kirn
Chief Executive Officer, Co-Founder, Director · since 2019
Chief Financial Officer and Principal Financial Officer · since 2025
Dhaval Desai
Chief Development Officer · since 2024
Robert Kim
Chief Medical Officer · since 2023
Christopher Simms
Chief Commercial Officer · since 2024
An Song
Chief Research & Translational Development Officer · since 2024
Scott Bizily
Chief Legal Officer and Corporate Secretary · since 2024
Director · since 2026
Independent Director · since 2019
Independent Director · since 2020
Independent Director · since 2020
Independent Director · since 2015
Independent Director · since 2020
IPO date
Dec 11, 2020
Employees
137
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||